Y-mAbs Therapeutics (NASDAQ: YMAB) has recently received a number of price target changes and ratings updates:

  • 6/1/2019 – Y-mAbs Therapeutics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Y-mAbs Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The company’s product pipeline consists of naxitamab and omburtamab which are in clinical stage. Y-mAbs Therapeutics Inc. is based in NEW YORK, USA. “
  • 5/28/2019 – Y-mAbs Therapeutics was given a new $36.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 5/24/2019 – Y-mAbs Therapeutics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Y-mAbs Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The company’s product pipeline consists of naxitamab and omburtamab which are in clinical stage. Y-mAbs Therapeutics Inc. is based in NEW YORK, USA. “
  • 5/18/2019 – Y-mAbs Therapeutics was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Y-mAbs Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The company’s product pipeline consists of naxitamab and omburtamab which are in clinical stage. Y-mAbs Therapeutics Inc. is based in NEW YORK, USA. “
  • 5/11/2019 – Y-mAbs Therapeutics was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Y-mAbs Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The company’s product pipeline consists of naxitamab and omburtamab which are in clinical stage. Y-mAbs Therapeutics Inc. is based in NEW YORK, USA. “
  • 5/3/2019 – Y-mAbs Therapeutics was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Y-mAbs Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The company’s product pipeline consists of naxitamab and omburtamab which are in clinical stage. Y-mAbs Therapeutics Inc. is based in NEW YORK, USA. “
  • 4/27/2019 – Y-mAbs Therapeutics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Y-mAbs Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The company’s product pipeline consists of naxitamab and omburtamab which are in clinical stage. Y-mAbs Therapeutics Inc. is based in NEW YORK, USA. “
  • 4/20/2019 – Y-mAbs Therapeutics was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Y-mAbs Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The company’s product pipeline consists of naxitamab and omburtamab which are in clinical stage. Y-mAbs Therapeutics Inc. is based in NEW YORK, USA. “

Shares of YMAB opened at $20.20 on Tuesday. Y-mAbs Therapeutics, Inc has a 1-year low of $15.17 and a 1-year high of $31.00. The firm has a market capitalization of $696.53 million and a P/E ratio of -13.47. The company has a debt-to-equity ratio of 0.02, a current ratio of 13.30 and a quick ratio of 13.30.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings results on Friday, March 22nd. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.11). As a group, sell-side analysts predict that Y-mAbs Therapeutics, Inc will post -1.95 earnings per share for the current fiscal year.

In related news, insider Thomas Gad sold 6,000 shares of the business’s stock in a transaction on Monday, May 13th. The shares were sold at an average price of $20.61, for a total value of $123,660.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders sold 262,000 shares of company stock valued at $6,717,420.

A number of institutional investors and hedge funds have recently made changes to their positions in YMAB. BNP Paribas Arbitrage SA purchased a new stake in shares of Y-mAbs Therapeutics in the first quarter valued at about $38,000. Citigroup Inc. purchased a new stake in shares of Y-mAbs Therapeutics in the fourth quarter valued at about $37,000. Strs Ohio purchased a new stake in shares of Y-mAbs Therapeutics in the fourth quarter valued at about $38,000. New York State Common Retirement Fund purchased a new stake in shares of Y-mAbs Therapeutics in the first quarter valued at about $63,000. Finally, American International Group Inc. purchased a new stake in shares of Y-mAbs Therapeutics in the fourth quarter valued at about $93,000. 24.80% of the stock is owned by hedge funds and other institutional investors.

Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.

Featured Article: What is the Ex-Dividend Date in Investing?

Receive News & Ratings for Y-mAbs Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.